FDA approves Sandoz’s Enzeevu as Eylea biosimilar saga continues
As Regeneron and Bayer fend off competition for Eylea copycats in the courts, Sandoz says Enzeevu will be a “key biosimilar value driver.”
As Regeneron and Bayer fend off competition for Eylea copycats in the courts, Sandoz says Enzeevu will be a “key biosimilar value driver.”
What's Your Reaction?
